CERo Therapeutics Holdings, Inc. Common Stock (CERO NASDAQ) stock market data APIs
$1.9218
0.04(2.1%)
as of October 24, 2025
Try our APIs with
free plan!
CERo Therapeutics Holdings, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Prev. Close
1.9218
Open
1.9607
High
2.0199
Low
1.8411
52 wk Range
1.84-896
Market Cap
3 562 K
Shares Outstanding
1 865 K
EPS
-61.71
Beta
0.436
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CERo Therapeutics Holdings, Inc. Common Stock data using free add-ons & libraries
Get CERo Therapeutics Holdings, Inc. Common Stock Fundamental Data
CERo Therapeutics Holdings, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -16 679 652
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get CERo Therapeutics Holdings, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-22
- EPS/Forecast: -6.21
Get CERo Therapeutics Holdings, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CERo Therapeutics Holdings, Inc. Common Stock News
New
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Ho...
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, annou...
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently pu...
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISC...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
